Business Description
Antengene Corp Ltd
ISIN : KYG039571008
Total Employee Number:
129Compare
Compare
Traded in other countries / regions
06996.Hong Kong722.Germany IPO Date
2021-05-07Description
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically, it operates in the Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.79 | |||||
Equity-to-Asset | 0.51 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | -1.21 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -4.2 | |||||
Beneish M-Score | 1.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.7 | |||||
3-Year EBITDA Growth Rate | 28.7 | |||||
3-Year EPS without NRI Growth Rate | 27.1 | |||||
3-Year FCF Growth Rate | 36.2 | |||||
3-Year Book Growth Rate | -28.1 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 81.4 | |||||
9-Day RSI | 71.32 | |||||
14-Day RSI | 62.61 | |||||
3-1 Month Momentum % | -32.14 | |||||
6-1 Month Momentum % | -5.47 | |||||
12-1 Month Momentum % | 30.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.97 | |||||
Quick Ratio | 2.94 | |||||
Cash Ratio | 2.72 | |||||
Days Inventory | 223.42 | |||||
Days Sales Outstanding | 78.86 | |||||
Days Payable | 113.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -1.12 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.59 | |||||
Operating Margin % | -200.01 | |||||
Net Margin % | -227.46 | |||||
EBITDA Margin % | -202.44 | |||||
FCF Margin % | -169.77 | |||||
OCF Margin % | -120.95 | |||||
ROE % | -32.16 | |||||
ROA % | -18.77 | |||||
ROIC % | -42.75 | |||||
3-Year ROIIC % | 230.81 | |||||
ROC (Joel Greenblatt) % | -91.65 | |||||
ROCE % | -22.01 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.08 | |||||
PS Ratio | 23.35 | |||||
PB Ratio | 3.72 | |||||
Price-to-Tangible-Book | 3.75 | |||||
EV-to-EBIT | -8.09 | |||||
EV-to-EBITDA | -8.99 | |||||
EV-to-Revenue | 18.21 | |||||
EV-to-Forward-Revenue | 23.65 | |||||
EV-to-FCF | -10.73 | |||||
Price-to-GF-Value | 3 | |||||
| Price-to-Net-Current-Asset-Value | 15 | |||||
| Price-to-Net-Cash | 22.5 | |||||
Earnings Yield (Greenblatt) % | -12.36 | |||||
FCF Yield % | -7.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Antengene Corp Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 12.745 | ||
| EPS (TTM) (€) | -0.046 | ||
| Beta | -0.7893 | ||
| 3-Year Sharpe Ratio | 0.64 | ||
| 3-Year Sortino Ratio | 2.05 | ||
| Volatility % | 118.96 | ||
| 14-Day RSI | 62.61 | ||
| 14-Day ATR (€) | 0.017134 | ||
| 20-Day SMA (€) | 0.3667 | ||
| 12-1 Month Momentum % | 30.14 | ||
| 52-Week Range (€) | 0.276 - 0.85 | ||
| Shares Outstanding (Mil) | 610.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Antengene Corp Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Antengene Corp Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-08-21 | In 47 days | ||
| General meeting for 2025 | 2026-06-10 | 0.35 (+0.00%) | ||
| Annual report for 2025 | 2026-04-29 | 0.53 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-20 | 0.43 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-22 | 0.70 (+0.00%) | ||
| General meeting for 2024 | 2025-06-13 10:30 | 0.45 (+0.00%) | ||
| Annual report for 2024 | 2025-04-27 | 0.31 (+0.00%) | ||
| Fourth quarter earnings conference call for 2024 | 2025-03-21 12:30 | 0.43 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-21 | 0.43 (+0.00%) | ||
| Second quarter earnings conference call for 2024 | 2024-08-23 09:00 | 0.03 (+0.00%) |
Show
Entries
Antengene Corp Ltd Frequently Asked Questions
What is Antengene Corp Ltd(FRA:722)'s stock price today?
The current price of FRA:722 is €0.45. The 52 week high of FRA:722 is €0.85 and 52 week low is €0.28.
When is next earnings date of Antengene Corp Ltd(FRA:722)?
The next earnings date of Antengene Corp Ltd(FRA:722) is 2026-08-21 Est..
Does Antengene Corp Ltd(FRA:722) pay dividends? If so, how much?
Antengene Corp Ltd(FRA:722) does not pay dividend.
Press Release
Articles on Antengene Corp Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers